|
WO1999061032A1
(en)
*
|
1998-05-25 |
1999-12-02 |
Nippon Shinyaku Co., Ltd. |
Process for producing composite preparation containing nucleic acid
|
|
EP2314700A1
(en)
*
|
1999-01-28 |
2011-04-27 |
Medical College of Georgia Research Institute, Inc |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
|
|
EP1097993A3
(en)
*
|
1999-11-05 |
2004-01-07 |
National Institute of Advanced Industrial Science and Technology |
Functional ribozyme chimeric molecules capable of sliding
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7461046B2
(en)
*
|
2002-02-07 |
2008-12-02 |
The University Of Utah Research Foundation |
Method for creating and using a treatment protocol
|
|
US20040180438A1
(en)
*
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
|
WO2003093449A2
(en)
*
|
2002-05-06 |
2003-11-13 |
Nucleonics, Inc. |
Methods for delivery of nucleic acids
|
|
JP2005529959A
(ja)
*
|
2002-06-14 |
2005-10-06 |
マイラス コーポレイション |
細胞へのポリヌクレオチドの伝達をするための新規な方法
|
|
EP1540004A4
(en)
*
|
2002-07-31 |
2007-10-03 |
Nucleonics Inc |
DOUBLE-STRING RNA STRUCTURES AND CONSTRUCTS AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
|
WO2004073631A2
(en)
*
|
2003-02-14 |
2004-09-02 |
Combinatorx, Incorporated |
Combination therapy for the treatment of neoplasms
|
|
HUE042261T2
(hu)
|
2003-06-12 |
2019-06-28 |
Alnylam Pharmaceuticals Inc |
Gén kikapcsolásra alkalmas konzervált HBV és HCV szekvenciák
|
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
|
JP2008514202A
(ja)
|
2004-09-24 |
2008-05-08 |
ニュークレオニクス・インコーポレイテッド |
Ｒｎａｉによる一本鎖ウイルスの逆鎖複製中間体のターゲティング
|
|
EP2316942B1
(en)
|
2004-12-22 |
2021-04-21 |
Alnylam Pharmaceuticals, Inc. |
Conserved hbv and hcv sequences useful for gene silencing
|
|
HRP20140338T1
(hr)
|
2005-07-25 |
2014-06-20 |
Emergent Product Development Seattle, Llc |
Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
|
|
WO2007146968A2
(en)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
|
DK2041270T3
(da)
|
2006-07-13 |
2014-01-27 |
Wyeth Llc |
Fremstilling af glycoproteiner
|
|
EP2799547B1
(en)
|
2006-11-08 |
2016-12-21 |
Veritas Bio, LLC |
In Vivo Delivery of RNA to a Target Cell
|
|
JP2010532764A
(ja)
*
|
2007-07-06 |
2010-10-14 |
トゥルビオン・ファーマシューティカルズ・インコーポレーテッド |
Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
|
|
EP2365003A1
(en)
|
2008-04-11 |
2011-09-14 |
Emergent Product Development Seattle, LLC |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
JP5883381B2
(ja)
|
2009-05-05 |
2016-03-15 |
ミラゲン セラピューティクス，インコーポレイテッド |
親油性ポリヌクレオチド接合体
|
|
CA2765129A1
(en)
|
2009-06-08 |
2010-12-16 |
Miragen Therapeutics |
Chemical modification motifs for mirna inhibitors and mimetics
|
|
WO2011121074A1
(en)
*
|
2010-04-01 |
2011-10-06 |
Pharmanest Ab |
Thermogelling anaesthetic compositions
|
|
WO2012061810A1
(en)
|
2010-11-05 |
2012-05-10 |
Miragen Therapeutics |
Base modified oligonucleotides
|
|
EA201370139A1
(ru)
|
2010-12-15 |
2013-10-30 |
Мираген Терапеутикс |
Ингибиторы микро-рнк, содержащие закрытые нуклеотиды
|
|
CA2832899A1
(en)
|
2011-04-12 |
2012-10-18 |
Beth Israel Deaconess Medical Center, Inc. |
Micro-rna inhibitors and their uses in disease
|
|
EP2755663A4
(en)
|
2011-09-13 |
2015-10-07 |
Ottawa Hospital Res Inst |
MicroRNA Inhibitors
|
|
US9388408B2
(en)
|
2012-06-21 |
2016-07-12 |
MiRagen Therapeutics, Inc. |
Oligonucleotide-based inhibitors comprising locked nucleic acid motif
|
|
CA2902571A1
(en)
|
2013-03-15 |
2014-09-18 |
MiRagen Therapeutics, Inc. |
Bridged bicyclic nucleosides
|
|
EP3068783B1
(en)
|
2013-11-15 |
2020-09-23 |
The Board of Trustees of the Leland Stanford Junior University |
Agonists of hypocretin receptor 2 for use for treating heart failure
|
|
US10772974B2
(en)
|
2013-11-18 |
2020-09-15 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for cardiac regeneration
|
|
CN108064175A
(zh)
|
2014-08-04 |
2018-05-22 |
米拉根医疗股份有限公司 |
Myh7b的抑制剂及其用途
|
|
AU2015315298B2
(en)
|
2014-09-08 |
2020-05-14 |
MiRagen Therapeutics, Inc. |
miR-29 mimics and uses thereof
|
|
US9885042B2
(en)
|
2015-01-20 |
2018-02-06 |
MiRagen Therapeutics, Inc. |
miR-92 inhibitors and uses thereof
|
|
MX368314B
(es)
|
2015-06-05 |
2019-09-27 |
Miragen Therapeutics Inc |
Inhibidores del mir-155 para tratar linfoma cutáneo de células t (ctcl).
|
|
EP3352760B1
(en)
|
2015-09-21 |
2026-03-11 |
Aptevo Research and Development LLC |
Cd3 binding polypeptides
|
|
WO2017087486A1
(en)
|
2015-11-16 |
2017-05-26 |
Ohio State Innovation Foundation |
Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein
|
|
EP3472193A4
(en)
|
2016-06-20 |
2020-01-08 |
The Board of Trustees of the Leland Stanford Junior University |
CIRCULAR RNA AND THEIR USE IN IMMUNOMODULATION
|
|
UY37376A
(es)
|
2016-08-26 |
2018-03-23 |
Amgen Inc |
Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
|
|
ES2659845B1
(es)
|
2016-09-19 |
2019-01-04 |
Univ Valencia |
Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
|
|
AR113490A1
(es)
|
2017-12-12 |
2020-05-06 |
Amgen Inc |
CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
|
|
BR112020018705A2
(pt)
|
2018-03-14 |
2021-01-05 |
Beth Israel Deaconess Medical Center |
Inibidores de microrna 22
|
|
CN113166761B
(zh)
|
2018-12-10 |
2025-09-09 |
美国安进公司 |
用于抑制pnpla3表达的rnai构建体
|
|
EP3894554A1
(en)
|
2018-12-10 |
2021-10-20 |
Amgen Inc. |
Chemically-modified rnai constructs and uses thereof
|
|
TW202111124A
(zh)
|
2019-05-30 |
2021-03-16 |
美商安進公司 |
用於抑制ｓｃａｐ表現之ｒｎａｉ構建體及其使用方法
|
|
WO2021030613A1
(en)
|
2019-08-13 |
2021-02-18 |
Amgen Inc. |
Rnai constructs for inhibiting slc30a8 expression and methods of use thereof
|
|
US20230078200A1
(en)
|
2019-12-09 |
2023-03-16 |
Amgen Inc. |
RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
|
|
WO2021234607A1
(en)
|
2020-05-20 |
2021-11-25 |
St. Jude Children's Research Hospital |
Detection of alzheimer's disease using specific biomarkers
|
|
MX2022015169A
(es)
|
2020-06-01 |
2023-07-03 |
Amgen Inc |
Constructos de arni para inhibir la expresion de hsd17b13 y metodos de uso de los mismos.
|
|
EP3929295A1
(en)
|
2020-06-26 |
2021-12-29 |
Universitat Pompeu Fabra |
Artificial rnas for modulating rna fragments
|
|
PE20230993A1
(es)
|
2020-08-13 |
2023-06-23 |
Amgen Inc |
Construcciones de iarn y metodos para inhibir la expresion de marc1
|
|
WO2022098841A1
(en)
|
2020-11-05 |
2022-05-12 |
Amgen Inc. |
METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
|
|
WO2023278295A1
(en)
|
2021-06-29 |
2023-01-05 |
The Broad Institute, Inc. |
Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
|
|
CN118556125A
(zh)
|
2021-10-05 |
2024-08-27 |
美国安进公司 |
用于增强寡核苷酸化合物的基因沉默活性的组合物和方法
|
|
CA3235262A1
(en)
|
2021-10-22 |
2023-04-27 |
Amgen Inc. |
Rnai constructs for inhibiting gpam expression and methods of use thereof
|
|
IL317825A
(en)
|
2022-07-25 |
2025-02-01 |
Amgen Inc |
RNA interference constructs and methods for inhibiting fam13a expression
|
|
EP4353823A1
(en)
|
2022-10-12 |
2024-04-17 |
Resalis Therapeutics S.r.l. |
Inhibitors of micro-rna 22
|
|
AR131389A1
(es)
|
2022-12-16 |
2025-03-12 |
Amgen Inc |
CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESIÓN DE TTR Y MÉTODOS DE USO DE LOS MISMOS
|
|
WO2025260042A1
(en)
|
2024-06-14 |
2025-12-18 |
Amgen Inc. |
Rnai constructs and methods for inhibiting cnr1 expression
|
|
WO2026006275A2
(en)
|
2024-06-26 |
2026-01-02 |
Amgen Inc. |
Rnai constructs and methods for inhibiting expression of inhbe
|